Journal
JOURNAL OF PERSONALIZED MEDICINE
Volume 12, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/jpm12121993
Keywords
malignant pleural mesothelioma (MPM); AXL; MET; targeted tyrosine kinase inhibitor (TKIs)
Ask authors/readers for more resources
Malignant pleural mesothelioma (MPM) is a highly lethal malignancy that cannot benefit from molecularly targeted therapies. This study found that the co-expression of AXL and MET receptors may play a key role in MPM patients, and the simultaneous inhibition of AXL and MET may affect the proliferation and aggressiveness of MPM cells.
Malignant pleural mesothelioma (MPM) is a highly lethal malignancy that unfortunately cannot benefit from molecularly targeted therapies. Although previous results showed the pivotal role of various receptor tyrosine kinases (RTKs) in MPM tumorigenesis, the treatment with a single inhibitor targeting one specific RTK has been shown to be ineffective in MPM patients. The main aim of the present study was to investigate the potential role of AXL and MET receptors in MPM and the possible efficacy of treatment with AXL and MET multitarget inhibitors. Immunohistochemical and FISH analyses were performed in a wide series of formalin-fixed paraffin-embedded MPM samples to detect the expression of two receptors and the potential gene amplification. In vitro studies were performed to evaluate putative correlations between the target's expression and the cell sensitivity to AXL-MET multitarget inhibitors. In our series, 10.4% of cases showed a co-expression of AXL and MET, regardless of their ligand expression, and the gene amplification. Furthermore, our in vitro results suggest that the concomitant pharmacological inhibition of AXL and MET may affect the proliferative and aggressiveness of MPM cells. In conclusion, the subset of MPM patients with AXL-MET co-activation could benefit from treatment with specific multitarget inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available